-
1.Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors 有权
标题翻译: 取代的N-(1H-吲唑-4-基)咪唑并[1,2-a]吡啶-3-甲酰胺化合物作为III型受体酪氨酸激酶抑制剂公开(公告)号:US09174981B2
公开(公告)日:2015-11-03
申请号:US13994048
申请日:2011-12-13
申请人: Mark Laurence Boys , Robert Kirk DeLisle , Erik James Hicken , April L. Kennedy , David A. Mareska , Fredrik P. Marmsater , Mark C. Munson , Brad Newhouse , Bryson Rast , James P. Rizzi , Martha E. Rodriguez , George T. Topalov , Qian Zhao
发明人: Mark Laurence Boys , Robert Kirk DeLisle , Erik James Hicken , April L. Kennedy , David A. Mareska , Fredrik P. Marmsater , Mark C. Munson , Brad Newhouse , Bryson Rast , James P. Rizzi , Martha E. Rodriguez , George T. Topalov , Qian Zhao
IPC分类号: C07D471/04
CPC分类号: C07D471/04 , A61K31/496 , A61K45/06
摘要: Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.
摘要翻译: 式I化合物及其药学上可接受的盐,其中R 1,R 2,R 3,R 4,R 5和R 6具有说明书中给出的含义,是cFMS的抑制剂,可用于治疗纤维化,骨相关疾病,癌症 ,自身免疫性疾病,炎性疾病,心血管疾病,哺乳动物的疼痛和灼伤。
-
2.SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS 有权
标题翻译: 取代的N-(1H-咪唑-4-基)咪唑并[1,2-]吡啶-3-羧酸酰胺化合物作为III型受体酪氨酸激酶抑制剂公开(公告)号:US20130274244A1
公开(公告)日:2013-10-17
申请号:US13994048
申请日:2011-12-13
申请人: Mark Laurence Boys , Robert Kirk Delisle , Erik James Hicken , April L. Kennedy , David A. Mareska , Fredrik P. Marmsater , Mark C. Munson , Brad Newhouse , Bryson Rast , James P. Rizzi , Martha E. Rodriguez , George T. Topalov , Qian Zhao
发明人: Mark Laurence Boys , Robert Kirk Delisle , Erik James Hicken , April L. Kennedy , David A. Mareska , Fredrik P. Marmsater , Mark C. Munson , Brad Newhouse , Bryson Rast , James P. Rizzi , Martha E. Rodriguez , George T. Topalov , Qian Zhao
IPC分类号: C07D471/04
CPC分类号: C07D471/04 , A61K31/496 , A61K45/06
摘要: Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.
摘要翻译: 式I化合物及其药学上可接受的盐,其中R 1,R 2,R 3,R 4,R 5和R 6具有说明书中给出的含义,是cFMS的抑制剂,可用于治疗纤维化,骨相关疾病,癌症 ,自身免疫性疾病,炎性疾病,心血管疾病,哺乳动物的疼痛和灼伤。
-
公开(公告)号:US20110144085A1
公开(公告)日:2011-06-16
申请号:US13059902
申请日:2009-08-18
申请人: Shelley Allen , Laura L. Celeste , T. Gregg Davis , Robert Kirk DeLisle , Julie Marie Greschuk , Stefan D. Gross , Erik James Hicken , Leila J. Jackson , Nicholas C. Kallan , Joseph P. Lyssikatos , Fredrik P. Marmsater , Mark C. Munson , Jed Pheneger , Bryson Rast , John E. Robinson , Stephen T. Schlachter , George T. Topalov , A. Dale Wright , Qian Zhao
发明人: Shelley Allen , Laura L. Celeste , T. Gregg Davis , Robert Kirk DeLisle , Julie Marie Greschuk , Stefan D. Gross , Erik James Hicken , Leila J. Jackson , Nicholas C. Kallan , Joseph P. Lyssikatos , Fredrik P. Marmsater , Mark C. Munson , Jed Pheneger , Bryson Rast , John E. Robinson , Stephen T. Schlachter , George T. Topalov , A. Dale Wright , Qian Zhao
IPC分类号: A61K31/55 , C07D471/04 , A61K31/437 , A61K31/513 , A61K31/5377 , A61P35/00 , A61P25/00 , A61P29/00
CPC分类号: C07D471/04
摘要: Compounds of Formula (I), in which A, B, R1, R1a, R2, R3, R4, R5, R6, and R7 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of immune cell-associated diseases and disorders, such as inflammatory and autoimmune diseases.
摘要翻译: 其中A,B,R1,R1a,R2,R3,R4,R5,R6和R7具有本说明书中给出的含义的式(I)化合物是可用于治疗免疫细胞相关的受体酪氨酸抑制剂 疾病和病症,例如炎性和自身免疫性疾病。
-
公开(公告)号:US08575145B2
公开(公告)日:2013-11-05
申请号:US13059902
申请日:2009-08-18
申请人: Shelley Allen , Laura L. Celeste , T. Gregg Davis , Robert Kirk DeLisle , Julie Marie Greschuk , Stefan D. Gross , Erik James Hicken , Leila J. Jackson , Nicholas C. Kallan , Joseph P. Lyssikatos , Fredrik P. Marmsater , Mark C. Munson , Jed Pheneger , Bryson Rast , John E. Robinson , Stephen T. Schlachter , George T. Topalov , A. Dale Wright , Qian Zhao
发明人: Shelley Allen , Laura L. Celeste , T. Gregg Davis , Robert Kirk DeLisle , Julie Marie Greschuk , Stefan D. Gross , Erik James Hicken , Leila J. Jackson , Nicholas C. Kallan , Joseph P. Lyssikatos , Fredrik P. Marmsater , Mark C. Munson , Jed Pheneger , Bryson Rast , John E. Robinson , Stephen T. Schlachter , George T. Topalov , A. Dale Wright , Qian Zhao
IPC分类号: A61K31/55 , A61K31/437 , A61K31/513 , A61K31/5377 , C07D471/04 , A61P35/00 , A61P25/00 , A61P29/00
CPC分类号: C07D471/04
摘要: Compounds of Formula (I), in which A, B, R1, R1a, R2, R3, R4, R5, R6, and R7 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of immune cell-associated diseases and disorders, such as inflammatory and autoimmune diseases.
摘要翻译: 其中A,B,R1,R1a,R2,R3,R4,R5,R6和R7具有本说明书中给出的含义的式(I)化合物是可用于治疗免疫细胞相关的受体酪氨酸抑制剂 疾病和病症,例如炎性和自身免疫性疾病。
-
公开(公告)号:US20110144100A1
公开(公告)日:2011-06-16
申请号:US13059881
申请日:2009-08-18
申请人: Shelley Allen , Robert Kirk DeLisle , Julie Marie Greschuk , Erik James Hicken , Joseph P. Lyssikatos , Fredrik P. Marmsater , Mark C. Munson , John E. Robinson , Qian Zhao
发明人: Shelley Allen , Robert Kirk DeLisle , Julie Marie Greschuk , Erik James Hicken , Joseph P. Lyssikatos , Fredrik P. Marmsater , Mark C. Munson , John E. Robinson , Qian Zhao
IPC分类号: A61K31/5377 , C07D471/04 , A61K31/496 , A61K31/4709 , A61P35/00 , A61P35/02 , A61P29/00 , A61P37/06 , A61P25/28
CPC分类号: C07D471/04
摘要: Compounds of Formula (I): I in which B, R1, R1a, R2, R3, R4, R5, R6, R7, R10 and R11 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of diseases mediated by PIM-1 and/or PIM-2 and/or PIM-3 kinases.
摘要翻译: 式(I)的化合物:其中B,R1,R1a,R2,R3,R4,R5,R6,R7,R10和R11具有本说明书中给出的含义的I是可用于治疗疾病介导的受体酪氨酸抑制剂 通过PIM-1和/或PIM-2和/或PIM-3激酶。
-
公开(公告)号:US08557809B2
公开(公告)日:2013-10-15
申请号:US13059881
申请日:2009-08-18
申请人: Shelley Allen , Robert Kirk DeLisle , Julie Marie Greschuk , Erik James Hicken , Joseph P. Lyssikatos , Fredrik P. Marmsater , Mark C. Munson , John E. Robinson , Qian Zhao
发明人: Shelley Allen , Robert Kirk DeLisle , Julie Marie Greschuk , Erik James Hicken , Joseph P. Lyssikatos , Fredrik P. Marmsater , Mark C. Munson , John E. Robinson , Qian Zhao
IPC分类号: A61K31/5377 , A61K31/496 , A61K31/4709 , C07D471/04 , A61P35/02 , A61P29/00
CPC分类号: C07D471/04
摘要: Compounds of Formula (I): I in which B, R1, R1a, R2, R3, R4, R5, R6, R7, R10 and R11 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of diseases mediated by PIM-1 and/or PIM-2 and/or PIM-3 kinases.
摘要翻译: 式(I)的化合物:其中B,R1,R1a,R2,R3,R4,R5,R6,R7,R10和R11具有本说明书中给出的含义的I是可用于治疗疾病介导的受体酪氨酸抑制剂 通过PIM-1和/或PIM-2和/或PIM-3激酶。
-
-
-
-
-